GO:0070527 platelet aggregation: Adhesion Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070527 platelet aggregation is defined as the adhesion of one platelet to one or more other platelets via adhesion molecules.
• Platelet aggregation is a central process in haemostasis and thrombosis and is a major target of antiplatelet drugs used in cardiovascular disease.
• The process is driven by platelet surface receptors and adhesion molecules, including integrin alphaIIbbeta3, GPIb-IX-V and P-selectin, which bridge platelets together.
• Exogenous factors such as snake venom disintegrins can modulate platelet aggregation and are important research tools.
• Platelet aggregation can be measured by aggregometry, single-platelet counting and PFA-100 devices, each with distinct advantages.
• Inhibiting platelet aggregation is a validated strategy for preventing thrombotic events, and natural products are being explored for primary prevention.
Description
Platelet aggregation (GO:0070527) is the biological process in which one platelet adheres to one or more other platelets via adhesion molecules. This process is fundamental to the formation of platelet plugs that seal vascular injuries, but when dysregulated it contributes to arterial thrombosis, atherosclerosis and ischaemic events. Because platelet aggregation is a final common pathway in thrombus formation, it is a major target for antiplatelet therapies used in coronary and peripheral vascular interventions. Research into platelet aggregation spans basic haemostasis, pharmacology, and the development of novel inhibitors from synthetic and natural sources. Exogenous factors from animal venoms, such as disintegrins, have also been shown to affect platelet aggregation and cancer proliferation, highlighting the broad biological relevance of this process. Understanding the molecular players and regulatory mechanisms of platelet aggregation is therefore essential for both fundamental biology and translational medicine.
platelet aggregation At A Glance
| GO ID | GO:0070527 |
|---|---|
| GO term | platelet aggregation |
| Ontology | biological_process |
| Synonym | blood platelet aggregation; thrombocyte aggregation |
| Major function | Adhesion of platelets to each other via adhesion molecules, leading to platelet plug formation |
| Cellular location | Platelet plasma membrane and extracellular space |
| Key molecules | Integrin alphaIIbbeta3, GPIb-IX-V, P-selectin, fibrinogen, von Willebrand factor |
| Related process | Haemostasis, thrombosis, atherosclerosis |
What Is GO:0070527?
According to the Gene Ontology, platelet aggregation (GO:0070527) is the adhesion of one platelet to one or more other platelets via adhesion molecules. This definition captures the homotypic cell-cell interaction that is mediated by specific surface receptors and their ligands, leading to platelet-platelet bridging and subsequent thrombus formation.
Why Is platelet aggregation Important in Cell Biology?
Platelet aggregation is a critical event in both normal haemostasis and pathological thrombosis. It is the target of widely used antiplatelet drugs such as aspirin and P2Y12 inhibitors, and understanding its mechanisms is essential for developing safer and more effective therapies. Moreover, platelet aggregation is implicated in atherosclerosis, cancer progression and inflammatory diseases, making it a broad biomedical research priority.
• Central to haemostasis and prevention of excessive bleeding.
• Key driver of arterial thrombosis and myocardial infarction.
• Major target for antiplatelet drugs in cardiovascular disease.
• Involved in the pathogenesis of atherosclerosis.
• Modulated by exogenous factors such as snake venom disintegrins.
• Measured in clinical and research settings to assess platelet function.
• Relevant to cancer progression and metastasis through platelet-tumour interactions.
• Provides a model for studying cell-cell adhesion and integrin signalling.
• Natural products are being investigated as inhibitors for primary prevention.
• Genetic and pharmacological modulation of platelet aggregation can inform personalised therapy.
What Happens During platelet aggregation?
Platelet Activation and Shape Change
In simple terms: Platelets become activated and change shape to prepare for sticking together.
Upon stimulation by agonists such as thrombin, ADP or collagen, platelets undergo activation, which involves a change from discoid to spherical form with pseudopod extension. This activation is a prerequisite for efficient aggregation and is accompanied by the release of granular contents that further recruit additional platelets.
Receptor-Mediated Adhesion
In simple terms: Adhesion molecules on the platelet surface bind to each other or to bridging molecules to link platelets together.
Platelet aggregation is mediated by adhesion molecules, as stated in the GO definition. Key receptors include integrin alphaIIbbeta3 (GPIIb/IIIa), which binds fibrinogen and von Willebrand factor to bridge adjacent platelets, and the GPIb-IX-V complex, which binds von Willebrand factor. These interactions are essential for stable platelet-platelet adhesion.
Inside-Out and Outside-In Signalling
In simple terms: Signals from inside the platelet activate adhesion receptors, and binding to ligands sends signals back into the platelet.
Integrin alphaIIbbeta3 undergoes inside-out signalling, where intracellular pathways triggered by agonist receptors convert the integrin to a high-affinity state for ligand binding. Subsequent outside-in signalling through the occupied integrin reinforces platelet activation, cytoskeletal reorganisation and aggregate stability.
Platelet-Platelet Bridging and Aggregate Formation
In simple terms: Multiple platelets become cross-linked into a growing clot.
Fibrinogen and von Willebrand factor act as bridging molecules that bind to activated integrin alphaIIbbeta3 on adjacent platelets, leading to the formation of platelet aggregates. This process is dynamic and reversible under certain conditions, and it is the target of antiplatelet agents such as GPIIb/IIIa inhibitors.
Inhibition and Exogenous Modulation
In simple terms: Various drugs and natural factors can block or alter platelet aggregation.
Platelet aggregation can be inhibited by pharmacological agents including aspirin, P2Y12 inhibitors and GPIIb/IIIa antagonists. Exogenous factors from animal sources, such as snake venom disintegrins, can also affect platelet aggregation by interacting with integrins, and these are valuable research tools.
Key Genes Involved in GO:0070527 platelet aggregation
The following genes and proteins are central to platelet aggregation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ITGA2B | Integrin alphaIIb subunit; forms alphaIIbbeta3 with ITGB3; binds fibrinogen and vWF to mediate platelet-platelet bridging | Target for antiplatelet drugs; mutations cause Glanzmann thrombasthenia |
| ITGB3 | Integrin beta3 subunit; partner of alphaIIb; essential for alphaIIbbeta3 function | Polymorphisms associated with platelet function and cardiovascular risk |
| GP1BA | Glycoprotein Ib alpha; component of GPIb-IX-V complex; binds vWF | Mutations cause Bernard-Soulier syndrome; target for antiplatelet research |
| GP1BB | Glycoprotein Ib beta; component of GPIb-IX-V complex | Involved in platelet adhesion to vWF |
| GP9 | Glycoprotein IX; component of GPIb-IX-V complex | Stabilises the GPIb-IX-V complex |
| VWF | Von Willebrand factor; bridges GPIb-IX-V to collagen and mediates platelet adhesion | Deficiency causes von Willebrand disease; target for thrombosis research |
| FGA | Fibrinogen alpha chain; forms fibrinogen that bridges activated alphaIIbbeta3 | Deficiency causes afibrinogenaemia; used in aggregation assays |
| FGB | Fibrinogen beta chain; component of fibrinogen | Relevant to platelet aggregation and clot formation |
| FGG | Fibrinogen gamma chain; component of fibrinogen | Mutations affect fibrinogen function and platelet aggregation |
| P2RY12 | P2Y12 receptor for ADP; amplifies platelet activation and aggregation | Target of clopidogrel and other antiplatelet drugs |
| TBXA2R | Thromboxane A2 receptor; mediates platelet activation and aggregation | Target of aspirin and thromboxane inhibitors |
| SELP | P-selectin; mediates platelet-leukocyte and platelet-platelet interactions | Marker of platelet activation; role in inflammation and thrombosis |
| SELPLG | P-selectin glycoprotein ligand-1; binds P-selectin | Involved in platelet-leukocyte aggregation |
| ITGAM | Integrin alphaMbeta2; expressed on leukocytes; can interact with platelets | Relevant to platelet-leukocyte aggregates |
| CD36 | Scavenger receptor; binds oxidized LDL and thrombospondin; modulates platelet aggregation | Linked to atherosclerosis and platelet hyperactivity |
| CLEC1B | C-type lectin-like receptor 2; receptor for podoplanin; activates platelets | Role in cancer-associated thrombosis |
| GP6 | Glycoprotein VI; collagen receptor; activates platelets | Target for antiplatelet therapy; involved in collagen-induced aggregation |
| ADRA2A | Alpha-2A adrenergic receptor; mediates adrenaline-induced platelet aggregation | Modulates platelet response to stress hormones |
How Is platelet aggregation Regulated?
Platelet aggregation is tightly regulated by intracellular signalling pathways. Agonist binding to G-protein-coupled receptors such as P2Y12 and thromboxane A2 receptor leads to activation of phospholipase C, increases in cytosolic calcium, and activation of protein kinase C, which together promote integrin alphaIIbbeta3 activation. Conversely, endothelial-derived inhibitors such as prostacyclin and nitric oxide elevate cyclic AMP and cyclic GMP, respectively, and suppress platelet activation and aggregation. The balance between pro-aggregatory and inhibitory signals determines the extent of platelet plug formation.
platelet aggregation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ITGA2B | Glanzmann thrombasthenia; defective platelet aggregation | Knockout or point-mutation in megakaryocytic cell lines; platelet function assays |
| ITGB3 | Glanzmann thrombasthenia; altered platelet aggregation | Knock-in of patient mutations in iPSC-derived megakaryocytes |
| GP1BA | Bernard-Soulier syndrome; defective platelet adhesion | Knockout in hematopoietic stem cells; flow-based adhesion assays |
| VWF | Von Willebrand disease; impaired platelet adhesion | Knockout mouse models; aggregation and adhesion studies |
| P2RY12 | Thrombosis; target of antiplatelet drugs | Knockout or point-mutation in platelet-like cells; aggregation assays |
Cardiovascular Thrombosis and Atherosclerosis
Excessive platelet aggregation is a key mechanism in arterial thrombosis, leading to myocardial infarction and ischaemic stroke. In atherosclerosis, platelet aggregation contributes to plaque instability and thrombus formation, and antiplatelet therapies are mainstays of treatment. Research into platelet aggregation in atherosclerosis models helps identify new therapeutic targets.
Bleeding Disorders
Defects in platelet aggregation cause bleeding disorders such as Glanzmann thrombasthenia, due to mutations in ITGA2B or ITGB3, and Bernard-Soulier syndrome, due to defects in the GPIb-IX-V complex. These conditions highlight the essential role of platelet aggregation in haemostasis.
Cancer and Thrombosis
Platelets can interact with cancer cells and promote tumour progression and cancer-associated thrombosis. Snake venom disintegrins that inhibit platelet aggregation have been studied for their effects on cancer proliferation, linking platelet aggregation pathways to oncology.
From platelet aggregation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ITGA2B abolish platelet aggregation? | ITGA2B knockout in megakaryocytic cell line (e.g., HEL or MEG-01) |
| Does a specific ITGB3 point mutation affect integrin activation? | Point-mutation knock-in in iPSC-derived megakaryocytes |
| Can a tagged GP1BA be used to track GPIb-IX-V trafficking? | Tagged knock-in of GP1BA in hematopoietic cells |
| Does overexpression of P2RY12 enhance platelet aggregation? | Overexpression of P2RY12 in platelet-like cells |
| What is the role of VWF in platelet-platelet bridging? | VWF knockout or knockdown in endothelial cells and platelets |
| Can CRISPR library screening identify novel regulators of platelet aggregation? | Genome-wide CRISPR knockout screen in megakaryocytic cell lines followed by aggregation assays |
How to Study the platelet aggregation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Light transmission aggregometry | Change in light transmission due to platelet clumping | Diagnosis of platelet function disorders; drug response |
| Single-platelet counting | Number of free platelets before and after aggregation | Alternative to aggregometry in clinical samples |
| PFA-100 | Closure time of a platelet plug under high shear | Screening for von Willebrand disease and platelet dysfunction |
| Flow cytometry | Surface markers of platelet activation (e.g., P-selectin) | Assessment of platelet activation state and platelet-leukocyte aggregates |
| Immunofluorescence microscopy | Localisation of platelet proteins and aggregate morphology | Studying cytoskeletal changes and integrin distribution |
| CRISPR knockout in megakaryocytic cells | Loss-of-function effects on platelet aggregation | Identifying essential genes for platelet aggregation |
| CRISPR knock-in of patient mutations | Effect of specific mutations on platelet function | Modeling inherited platelet disorders |
| CRISPR activation (overexpression) | Gain-of-function effects on platelet aggregation | Testing sufficiency of a gene in promoting aggregation |
Platelet Aggregometry
Light transmission aggregometry is the classic method to measure platelet aggregation in platelet-rich plasma or washed platelets, based on the increase in light transmission as platelets clump. It is widely used in clinical and research settings to assess responses to agonists and inhibitors.
Single-Platelet Counting and PFA-100
Single-platelet counting and PFA-100 devices provide alternative measures of platelet aggregation and adhesion under flow conditions. These methods can be useful when aggregometry is not feasible and offer insights into primary haemostasis.
Flow Cytometry and Imaging
Flow cytometry can detect platelet activation markers such as P-selectin and activated integrin alphaIIbbeta3, as well as platelet-leukocyte aggregates. Imaging techniques, including confocal and electron microscopy, allow visualisation of platelet aggregate formation and ultrastructure.
Genetic and Pharmacological Modulation
CRISPR-based knockout or knock-in of genes such as ITGA2B, ITGB3 and GP1BA in megakaryocytic cell lines or iPSC-derived megakaryocytes enables causal testing of gene function in platelet aggregation. Pharmacological inhibitors, including aspirin and P2Y12 antagonists, are used to probe pathways and as positive controls.
How CRISPR Can Be Used to Study GO:0070527 platelet aggregation
Knockout
CRISPR knockout of genes such as ITGA2B, ITGB3 or GP1BA in megakaryocytic cell lines or primary hematopoietic cells can abolish platelet aggregation, providing direct evidence of their essential roles. Knockout studies help distinguish genes required for platelet activation versus those needed for aggregation per se.
Point Mutation
Introducing disease-associated point mutations (e.g., in ITGB3 or GP1BA) via CRISPR base editing or homology-directed repair allows researchers to model inherited platelet disorders and dissect signalling defects. Such models are valuable for testing targeted therapies.
Knock-in
Knock-in of tagged versions of platelet proteins (e.g., GFP-tagged GP1BA) enables real-time tracking of receptor trafficking and localisation during aggregation. Knock-in of reporter genes under endogenous promoters can also provide sensitive readouts of platelet activation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes such as P2RY12 or TBXA2R can enhance platelet aggregation and help identify gain-of-function mechanisms. Overexpression models are useful for testing whether a gene is sufficient to drive aggregation.
How EDITGENE Supports platelet aggregation Research
Researchers studying platelet aggregation-related genes often need to determine whether a candidate gene is causally involved in platelet-platelet adhesion or is merely a bystander. CRISPR-based models provide the gold standard for such causal inference, enabling precise genetic perturbations in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for platelet aggregation research.
Frequently Asked Questions About platelet aggregation
What is platelet aggregation?
Platelet aggregation is the adhesion of one platelet to one or more other platelets via adhesion molecules, as defined by GO:0070527.
What genes are involved in platelet aggregation?
Key genes include ITGA2B, ITGB3, GP1BA, GP1BB, GP9, VWF, FGA, FGB, FGG, P2RY12, TBXA2R, SELP and GP6, among others.
How is platelet aggregation measured?
It can be measured by light transmission aggregometry, single-platelet counting, PFA-100 and flow cytometry.
What diseases are associated with abnormal platelet aggregation?
Thrombosis, atherosclerosis, Glanzmann thrombasthenia and Bernard-Soulier syndrome are associated with altered platelet aggregation.
What drugs inhibit platelet aggregation?
Aspirin, P2Y12 inhibitors (e.g., clopidogrel) and GPIIb/IIIa antagonists are common antiplatelet drugs.
Can natural products affect platelet aggregation?
Yes, many herbs and natural compounds have been studied for their ability to inhibit platelet aggregation, with evidence from randomized controlled trials.
How do snake venom disintegrins affect platelet aggregation?
Snake venom disintegrins can inhibit platelet aggregation by blocking integrin alphaIIbbeta3, and they also affect cancer proliferation.
What is the role of integrin alphaIIbbeta3 in platelet aggregation?
Integrin alphaIIbbeta3 binds fibrinogen and von Willebrand factor to bridge adjacent platelets, a central step in aggregation.
Can CRISPR be used to study platelet aggregation?
Yes, CRISPR knockout, knock-in and overexpression in megakaryocytic cell lines or iPSC-derived megakaryocytes enable causal studies of platelet aggregation genes.
What is the GO term for platelet aggregation?
The Gene Ontology term is GO:0070527, named platelet aggregation, under biological_process.
Conclusion
Platelet aggregation (GO:0070527) is a fundamental biological process with critical roles in haemostasis and thrombosis. Its molecular basis involves adhesion molecules such as integrin alphaIIbbeta3 and the GPIb-IX-V complex, and it is regulated by intricate signalling pathways. Dysregulated platelet aggregation contributes to cardiovascular disease, bleeding disorders and cancer-associated thrombosis, making it a key target for therapeutic intervention. Advances in CRISPR-based models and screening technologies are poised to accelerate the discovery of new regulators and treatments for platelet aggregation-related conditions.
References
- 1. Nouruzi S et al.. 2022. Platelet Aggregation Inhibition: An Evidence-Based Systematic Review on the Role of Herbs for Primary Prevention Based on Randomized Controlled Trials.. Iran J Med Sci 47(6):505-516 PMID: 36380973
- 2. Xie Z et al.. 2019. Developments in inhibiting platelet aggregation based on different design strategies.. Future Med Chem 11(14):1757-1775 PMID: 31288579
- 3. Lordan R et al.. 2022. Investigation of Platelet Aggregation in Atherosclerosis.. Methods Mol Biol 2419:333-347 PMID: 35237975
- 4. Dovlatova N et al.. 2018. Platelet aggregation measured by single-platelet counting and using PFA-100 devices.. Platelets 29(7):656-661 PMID: 29985716
- 5. Kolvekar N et al.. 2023. How snake venom disintegrins affect platelet aggregation and cancer proliferation.. Toxicon 221:106982 PMID: 36435228
- 6. Shlansky-Goldberg R. 2002. Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries?. J Vasc Interv Radiol 13(3):229-46 PMID: 11875083
- 7. Nenci GG. 1987. Platelet aggregation and platelet-inhibiting drugs.. Neurochem Pathol 7(1):23-32 PMID: 3328834
- 8. Kini RM. 2004. Platelet aggregation and exogenous factors from animal sources.. Curr Drug Targets Cardiovasc Haematol Disord 4(4):301-25 PMID: 15578956
